Abiopharma

Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors

Cidara Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes

Protara Therapeutics Announces Addition to the Russell 3000® Index

Intensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST)

Allarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion Diagnostic

Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live’25

Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors

Clene Provides Regulatory Update Following Constructive FDA Type-C Meeting on Neurofilament Biomarker Analysis Plan and Confirms Two Additional FDA Meetings

New Form NT 10-K - DH ENCHANTMENT, INC. Filed: 2025-06-30 AccNo: 0001683168-25-004801 Size: 20 KB

New Form 6-K - ARGENX SE Filed: 2025-06-30 AccNo: 0001104659-25-063821 Size: 27 KB

Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain

Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain

New Form 8-K - BIOCRYST PHARMACEUTICALS INC Filed: 2025-06-30 AccNo: 0001140361-25-024089 Size: 2 MB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits

INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer’s Diseas

New Form 6-K - NuCana plc Filed: 2025-06-30 AccNo: 0001193125-25-151990 Size: 305 KB